| Autor: |
Neurath, Markus Friedrich, Sands, Bruce Eric, Rieder, Florian |
| Zdroj: |
Gut; 2025, Vol. 74 Issue: 1 p9-14, 6p |
| Abstrakt: |
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
